结核患者一线抗结核药治疗药物监测的最佳采样策略
本研究在结核患者治疗前3天开展前瞻性随机交叉试验,比较静脉、空腹及餐后给药条件,利用最佳子集多元线性回归开发AUC24预测的最佳采样策略(OSS)。结果显示2、4、8小时三点采样预测效果最佳,除餐后条件下乙胺丁醇外,各药偏倚<5%、不精密度<15%;外部验证提示该策略不能用于稳态下利福平的预测。
要点
- 2、4、8小时三点采样可准确预测一线抗结核药的AUC24。
- 除餐后乙胺丁醇外,各药偏倚<5%、不精密度<15%。
- 该OSS不能用于稳态条件下利福平的AUC24预测。
核心结论
- 给药后2、4、8小时采样的OSS可在该人群中准确、精密地预测一线抗结核药的AUC24值。
研究设计与样本
- 前瞻性随机交叉试验,在结核患者治疗前3天比较静脉、空腹及餐后给药条件。
- 利用最佳子集多元线性回归开发OSS,并以jackknife法内部验证、以不同种族稳态治疗患者外部验证。
主要发现
- 2、4、8小时三点采样的OSS表现最佳。
- 除餐后条件下乙胺丁醇外,所有药物的偏倚<5%、不精密度<15%。
- 外部验证显示OSS2-4-8不能用于稳态条件下的利福平。
关键数值与推荐
- 偏倚<5%、不精密度<15%(除餐后乙胺丁醇外)。
- 外部验证:OSS2-4-8不适用于稳态下利福平。
临床怎么用
- 在治疗早期可采用给药后2、4、8小时三点采样估算一线抗结核药AUC24。
- 稳态条件下不宜用该OSS预测利福平AUC24。
局限性
- 餐后条件下乙胺丁醇的预测精度未达偏倚<5%、不精密度<15%的标准。
- OSS2-4-8不能用于稳态条件下利福平的AUC24预测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The 24-h area under the concentration-time curve (AUC24)/minimal inhibitory concentration ratio is the best predictive pharmacokinetic/pharmacodynamic (PK/PD) parameter of the efficacy of first-line anti-tuberculosis (TB) drugs. An optimal sampling strategy (OSS) is useful for accurately estimating AUC24; however, OSS has not been developed in the fed state or in the early phase of treatment for first-line anti-TB drugs. METHODS: An OSS for the prediction of AUC24 of isoniazid, rifampicin, ethambutol and pyrazinamide was developed for TB patients starting treatment. A prospective, randomized, crossover trial was performed during the first 3 days of treatment in which first-line anti-TB drugs were administered either intravenously or in fasting or fed conditions. The PK data were used to develop OSS with best subset selection multiple linear regression. The OSS was internally validated using a jackknife analysis and externally validated with other patients from different ethnicities and in a steady state of treatment. RESULTS: OSS using time points of 2, 4 and 8 h post-dose performed best. Bias was < 5% and imprecision was < 15% for all drugs except ethambutol in the fed condition. External validation showed that OSS2-4-8 cannot be used for rifampicin in steady state conditions. CONCLUSION: OSS at 2, 4 and 8 h post-dose enabled an accurate and precise prediction of AUC24 values of first-line anti-TB drugs in this population. TRIAL REGISTRATION: ClinicalTrials.gov (NCT02121314).
引用
- Saktiawati AMI, Harkema M, Setyawan A, et al. Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with Tuberculosis. Clin Pharmacokinet. 2019. PMID: 30997650. doi:10.1007/s40262-019-00763-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。